Ronald Newbold
Directeur/Membre du Conseil chez The University of Virginia Patent Foundation
Profil
Ronald C.
Newbold is currently the Vice Chairman at The University of Virginia Patent Foundation.
Previously, he held senior positions at Merck & Co., Inc., Sentigen Holding Corp., AVANT Immunotherapeutics, Inc., Celldex Therapeutics, Inc. (Old), Auspex Pharmaceuticals, Inc., and Sentigen Biosciences, Inc. He also served as the Vice President of Business Development at Celldex Therapeutics, Inc. Dr. Newbold holds a doctorate from the University of Rochester and an MBA from The Trustees of Columbia University in The City of New York.
Postes actifs de Ronald Newbold
| Sociétés | Poste | Début |
|---|---|---|
The University of Virginia Patent Foundation
 The University of Virginia Patent Foundation Miscellaneous Commercial ServicesCommercial Services The University of Virginia Patent Foundation was founded in 1977 and operates as a civic and social association. The private company is based in Charlottesville, VA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Ronald Newbold
| Sociétés | Poste | Fin |
|---|---|---|
Sentigen Holding Corp.
 Sentigen Holding Corp. BiotechnologyHealth Technology Sentigen Holding Corp. provides research and development services for drug discovery. The company study and evaluate protein interaction. The company is headquartered in Phillipsburg, NJ. | Directeur des opérations | 27/04/2011 |
| CELLDEX THERAPEUTICS, INC. | Corporate Officer/Principal | 30/01/2009 |
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Corporate Officer/Principal | 01/10/2008 |
| Sentigen Biosciences, Inc. | Corporate Officer/Principal | 01/01/2004 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2000 |
Formation de Ronald Newbold
| Rochester Christian University | Doctorate Degree |
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| Entreprise privées | 6 |
|---|---|
Sentigen Holding Corp.
Sentigen Holding Corp. BiotechnologyHealth Technology Sentigen Holding Corp. provides research and development services for drug discovery. The company study and evaluate protein interaction. The company is headquartered in Phillipsburg, NJ. | Health Technology |
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Celldex Therapeutics, Inc. (Old)
 Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Health Technology |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA. | Health Technology |
| Sentigen Biosciences, Inc. | |
The University of Virginia Patent Foundation
The University of Virginia Patent Foundation Miscellaneous Commercial ServicesCommercial Services The University of Virginia Patent Foundation was founded in 1977 and operates as a civic and social association. The private company is based in Charlottesville, VA. | Commercial Services |